GlassScriptPhysician profile
Jennifer M Carter
NPI 1891136644
$3,326.24
in general payments reported to CMS, 2019-2025
38 companies · $91.16 in 2025
The $91.16 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.51 · 2020: $274 · 2021: $836 · 2022: $607 · 2023: $567 · 2024: $914 · 2025: $91.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.14 |
| Education | $260.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $341.24 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $234.79 | 2020-2024 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $187.62 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.72 | 2023-2024 | Ninlaro, Fruzaqla, Iclusig |
| Astellas Pharma US INC | $177.71 | 2020-2025 | Padcev, Xospata, Cresemba |
| Exelixis INC. | $173.63 | 2020-2024 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $162.06 | 2020-2024 | Lynparza, Imfinzi |
| Amgen INC. | $160.61 | 2020-2023 | Blincyto, Kyprolis |
| Seagen INC. | $147.29 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Incyte Corporation | $146.07 | 2023-2024 | Jakafi, Monjuvi |
| Emd Serono, INC. | $130.00 | 2024 | |
| Abbvie INC. | $112.25 | 2024-2025 | |
| Sobi, INC | $108.22 | 2023 | |
| Eisai INC. | $105.92 | 2020-2024 | |
| Genzyme Corporation | $101.44 | 2021-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.